Skip to content

Evaluation of immunogenicity and reactogenicity of heterologous covid-19 vaccine combination ChAdOx-1S followed by BNT162b2

Evaluation of immunogenicity and reactogenicity of heterologous covid-19 vaccine combination ChAdOx-1S followed by BNT162b2 - Covid vaccine combination AstraZeneca and Biontech

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
DRKS
Registry ID
DRKS00025271
Enrollment
154
Registered
2021-05-11
Start date
2021-05-19
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prevention covid

Interventions

Group 1: The intervention is two blood draws. One before and one after the decond vaccination in order to evaluate the effect of the vaccination. The vaccination as such is recommended and thus not pa

Sponsors

Uniklinik Regensburg Abteilung für Hygiene und Infektiologie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: There had been vaccinated 154 HCW of the university clinics of Regensburg an March 15, 2021 with the Astrazeneca vaccine. Everyone who wants to receive the second dose with the vaccine from Biontech is offered the participation in the study.

Exclusion criteria

Exclusion criteria: First Covid vaccination not with Astrazeneca. contraindication to vaccination with biontech vaccine

Design outcomes

Primary

MeasureTime frame
Blood draws before and 4(-6) weeks after the second vaccination with determination of anti-SARS-Cov-2-antiodies in serum by ELISA. A questionnaire will be handed out and collected at date of second blood draw. Side effects of first and second dose will be asked for.

Secondary

MeasureTime frame
Comparison of antibody titers with those of vaccinees of another study who received the Biontech vaccine twice

Countries

Germany

Contacts

Public ContactStilla Bauernfeind

Uniklinik Regensburg Abteilung für Hygiene und Infektiologie

stilla.bauernfeind@ukr.de0941 944 4250

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026